Gossamer Q2 net income $16.9M; NDA on track Sept 2026; reacquires seralutinib rights

Gossamer Bio, Inc.

2026-Q2 EPS reported -$0.24 revenue$26,193,000

Q2 2026 net income $16.9M vs net loss $38.3M in Q2 2025; revenue $9.2M from Chiesi collaboration.
NDA submission for seralutinib in PAH on track for Sept 2026; FDA feedback from Pre-NDA Type B meeting; potential approval decision Q3 2027.
Reacquired worldwide rights to seralutinib from Chiesi; no upfront cash, Chiesi gets capped royalty and milestone payments.
Exchanged $181.1M of 5.00% 2027 notes for $65.2M new 7.50% 2030 notes, reducing debt by ~$115.9M; 2027 notes now ~$18.9M.
Cash $57.0M at June 30, 2026; expected to fund operations into Q1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.